DUBLIN–(BUSINESS WIRE)–The “Global
Urticaria Clinical Trial Pipeline Highlights – 2019” report has
been added to ResearchAndMarkets.com’s offering.
Urticaria Pipeline Highlights – 2019 provides most up-to-date
information on key pipeline products in the global Urticaria market. It
covers emerging therapies for Urticaria in active clinical development
stages including early and late stage clinical trials. The pipeline data
presented in this report helps executives for tracking competition,
identifying partners, evaluating opportunities, formulating business
development strategies, and executing in-licensing and out-licensing
deals.
Clinical Trial Stages:
The report provides Urticaria pipeline products by clinical trial stages
including both early and late stage development – phase 3 clinical
trials, phase 2 clinical trials, phase 1 clinical trials, preclinical
research, and discovery stage.
Drug Mechanism Classes:
The report provides Urticaria pipeline products by their dominant
mechanism of action/drug class. This helps executives categorize
products based on their drug class and also assess the strengths and
weaknesses of compounds.
Company:
The report provides Urticaria pipeline products by the company.
Short-term Launch Highlights:
Find out which Urticaria pipeline products will be launched in the US
and Ex-US till 2024.
Key Topics Covered:
1. Urticaria Pipeline by Stages
2. Urticaria Phase 3 Clinical Trial Insights
3. Urticaria Phase 2 Clinical Trial Insights
4. Urticaria Phase 1 Clinical Trial Insights
5. Urticaria Preclinical Research Insights
6. Urticaria Discovery Stage Insights
7. Appendix
8. Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/tcd7xx
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Clinical
Trials, Dermatological
Drugs